
Navigating 2025: Three Key Trends Shaping the Future of Pharma
Here are three key trends that pharma leaders and clinical operations teams should monitor this year, along with a checklist of strategic priorities to stay ahead.
Here are three key trends that pharma leaders and clinical operations teams should monitor this year, along with a checklist of strategic priorities to stay ahead.
Precision medicine relies on understanding how differences affect drug response. Researchers can develop more precise treatments that are effective for more patients when prioritizing diversity.
As the clinical trial landscape evolves, prioritizing inclusion, innovation, and scalability is essential for accelerating the development of safe and effective treatments that truly meet the needs of diverse patient populations.
Hospitals and health systems stand at the forefront of advancing health equity and carry the heavy responsibility of treating illness while promoting wellness and reducing disparities in health outcomes.
When diversity is well-implemented in healthcare materials, trust is built and patient-provider relationships improve. It also enhances the medical accuracy of the information presented.
The $100 million investment will sponsor 10,000 clinicians from underrepresented racial groups who are pursuing or advancing careers in healthcare. It is the single largest philanthropic commitment ever made by the United Health Foundation.
By accessing community care networks (CCNs), payer organizations and providers can enable a holistic patient approach that includes social determinants of health ,and diversity, equity and inclusion in its design.
Stand Up To Cancer, a nonprofit that supports funding for cancer research, launched a new initiative to expand minority representation in clinical trials. The nonprofit will seek proposals later this year to fund projects researching cancers that disproportionately affect members of a specific racial or ethnic background.
BIO's first annual report on diversity in the workplace found room for improvement, as biotech workforces - especially at the executive level - were found to not represent the U.S. population. The report was based on a survey of nearly 100 companies in late spring 2019.
Experts said the rise of cutting-edge new therapies highlighted disparities between clinical trial populations and the patients receiving new drugs. An FDA draft guidance earlier this month sought to address the issue.
A new report by Paubox calls for healthcare IT leaders to dispose of outdated assumptions about email security and address the challenges of evolving cybersecurity threats.
At BIO Tuesday, panelists discussed the lack of racial, ethnic and gender diversity in clinical trials and its potential implications.
The University City Science Center's DHA program created a blind initial application process that focuses on the founders’ ability to communicate their idea with the goal of removing biases associated with how screeners perceive the founding team.
ConsejoSano founder and CEO Abner Mason talks about the importance of understanding different patients' cultures and languages to help them engage the healthcare system
One attendee called the PABNAB party entertainment "tone-deaf," but it's not the first event of its kind at a biotech show.
I have seen how difficult it is for even very skilled, very qualified women to get placed on a board, and it has renewed my commitment to being an ally in this fight for gender diversity.